{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:42:36Z","timestamp":1772160156352,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate early glycaemic control (glycated haemoglobin [HbA1c]\u2009&lt;\u20097.0% [&lt;53.0\u2009mmol\/mol], fasting plasma glucose [FPG]\u2009\u2264\u20097.0\u2009mmol\/L or postprandial glucose [PPG]\u2009\u2264\u200910.0\u2009mmol\/L) with iGlarLixi versus insulin glargine 100\u2009U\/mL (Gla\u2010100) in Asian people with suboptimally controlled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs) in LixiLan\u2010O\u2010AP or basal insulin (BI)\u2009\u00b1\u2009OADs in LixiLan\u2010L\u2010CN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated changes from baseline to Week 12 in HbA1c, FPG and PPG, hypoglycaemia incidence and the rates of target HbA1c achievement at Weeks 8 and 12. Median time to glycaemic control (i.e., time to 50% achieving target HbA1c, FPG or PPG) was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At Week 12, mean HbA1c reductions were greater with iGlarLixi versus Gla\u2010100 in LixiLan\u2010O\u2010AP (\u22121.6% vs. \u22121.1% [\u221217.0 vs. \u221212.0\u2009mmol\/mol]) and LixiLan\u2010L\u2010CN (\u22121.3% vs. \u22120.5% [\u221213.9 vs. \u22125.4\u2009mmol\/mol]). PPG reductions were greater with iGlarLixi, while FPG reductions and hypoglycaemia incidence were similar. At Weeks 8 and 12, more participants had achieved target HbA1c or PPG with iGlarLixi versus Gla\u2010100 in both studies. Median time to achieve HbA1c and PPG targets was shorter with iGlarLixi versus Gla\u2010100 in LixiLan\u2010O\u2010AP (85 vs. 126\u2009days and 84 vs. 167\u2009days) and LixiLan\u2010L\u2010CN (85 vs. 239\u2009days and 85\u2009days vs. not estimable); median time to achieve FPG target was similar in LixiLan\u2010O\u2010AP (57 vs. 57\u2009days) and LixiLan\u2010L\u2010CN (29 vs. 30\u2009days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Asian people with T2D suboptimally controlled on OADs or BI, iGlarLixi provided comprehensive earlier glycaemic control than Gla\u2010100.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16260","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:43:36Z","timestamp":1740894216000},"page":"2593-2600","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<scp>iGlarLixi<\/scp>\n                    provides improved early glycaemic control after 12\u2009weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the\n                    <scp>LixiLan<\/scp>\n                    \u2010O\u2010\n                    <scp>AP<\/scp>\n                    and\n                    <scp>LixiLan<\/scp>\n                    \u2010L\u2010\n                    <scp>CN<\/scp>\n                    studies"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0705-8873","authenticated-orcid":false,"given":"Lulu","family":"Song","sequence":"first","affiliation":[{"name":"China\u2010Japan Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-7034","authenticated-orcid":false,"given":"Xiaoyong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8125-953X","authenticated-orcid":false,"given":"Shan","family":"Huang","sequence":"additional","affiliation":[{"name":"Shanghai Tongren Hospital  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pingxiang City People's Hospital  Pingxiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Lauand","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhini","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-9404","authenticated-orcid":false,"given":"Wenying","family":"Yang","sequence":"additional","affiliation":[{"name":"China\u2010Japan Friendship Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5588-0995","authenticated-orcid":false,"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.07.007"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_4_1","unstructured":"National Medical Products Administration China.Delivery of drug approval certificates [in Chinese].2023. Accessed May 21 2024.https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20230113151759128.html"},{"key":"e_1_2_10_5_1","unstructured":"Pharmaceutical and Medical Devices Agency Japan.New drugs approved in FY 2019.2020. Accessed May 21 2024.https:\/\/www.pmda.go.jp\/files\/000267880.pdf"},{"key":"e_1_2_10_6_1","unstructured":"US Food and Drug Administration.Soliqua\u00ae 100\/33 (insulin glargine and lixisenatide) injection for subcutaneous use: prescribing information.2016. Accessed May 21 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208673s012lbl.pdf"},{"key":"e_1_2_10_7_1","unstructured":"European Medicines Agency.Suliqua (insulin glargine and lixisenatide): summary of product characteristics.2017. Accessed May 21 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/suliqua-epar-product-information_en.pdf"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0602-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01196-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2011.00109.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2012.00193.x"},{"key":"e_1_2_10_12_1","first-page":"315","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition) [in Chinese]","volume":"13","author":"Chinese Diabetes Society","year":"2021","journal-title":"Chin J Diabetes"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14803"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14722"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15074"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13368"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S006"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00537-3"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0016"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S328165"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:55:16Z","timestamp":1761864916000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/dom.16260"],"URL":"https:\/\/doi.org\/10.1111\/dom.16260","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16260\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16260\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16260\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16260\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16260\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16260\/v1\/review2","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2024-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}